What about taking only osimertinib/osimertinib without radiotherapy for lung cancer?

For patients with advanced non-small cell lung cancer (NSCLC), especially those with EGFR (epidermal growth factor receptor) mutation-positive patients, osimertinib/osimertinib has been widely used as a first-line treatment drug. Compared with radiation therapy, osimertinib alone may have better therapeutic effects in some cases, especially in patients with EGFR mutations. Osimertinib/Osimertinib is a targeted therapy drug that can directly intervene in the pathogenic mechanism of tumor cells by inhibiting EGFR kinase activity. Compared with traditional radiotherapy, Osimertinib can not only reduce treatment-related toxic side effects, but also significantly extend progression-free survival and overall survival.